Kukje Pharma Co Ltd (002720) - Net Assets
Based on the latest financial reports, Kukje Pharma Co Ltd (002720) has net assets worth ₩95.32 Billion KRW (≈ $64.60 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩180.12 Billion ≈ $122.06 Million USD) and total liabilities (₩84.80 Billion ≈ $57.47 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Kukje Pharma Co Ltd (002720) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩95.32 Billion |
| % of Total Assets | 52.92% |
| Annual Growth Rate | 1.39% |
| 5-Year Change | 27.02% |
| 10-Year Change | 30.81% |
| Growth Volatility | 14.37 |
Kukje Pharma Co Ltd - Net Assets Trend (2011–2024)
This chart illustrates how Kukje Pharma Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore 002720 current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Kukje Pharma Co Ltd (2011–2024)
The table below shows the annual net assets of Kukje Pharma Co Ltd from 2011 to 2024. For live valuation and market cap data, see Kukje Pharma Co Ltd (002720) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩89.55 Billion ≈ $60.69 Million |
+5.41% |
| 2023-12-31 | ₩84.95 Billion ≈ $57.57 Million |
+14.67% |
| 2022-12-31 | ₩74.08 Billion ≈ $50.20 Million |
+8.01% |
| 2021-12-31 | ₩68.59 Billion ≈ $46.48 Million |
-2.71% |
| 2020-12-31 | ₩70.50 Billion ≈ $47.78 Million |
+15.66% |
| 2019-12-31 | ₩60.95 Billion ≈ $41.31 Million |
-11.27% |
| 2018-12-31 | ₩68.70 Billion ≈ $46.56 Million |
+1.36% |
| 2017-12-31 | ₩67.78 Billion ≈ $45.93 Million |
+0.38% |
| 2016-12-31 | ₩67.52 Billion ≈ $45.76 Million |
-1.37% |
| 2015-12-31 | ₩68.46 Billion ≈ $46.39 Million |
+34.62% |
| 2014-12-31 | ₩50.85 Billion ≈ $34.46 Million |
-12.82% |
| 2013-12-31 | ₩58.33 Billion ≈ $39.53 Million |
+5.38% |
| 2012-12-31 | ₩55.35 Billion ≈ $37.51 Million |
-25.99% |
| 2011-12-31 | ₩74.79 Billion ≈ $50.69 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Kukje Pharma Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 540638464000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩5.41 Billion | 6.04% |
| Other Components | ₩84.14 Billion | 93.96% |
| Total Equity | ₩89.54 Billion | 100.00% |
Kukje Pharma Co Ltd Competitors by Market Cap
The table below lists competitors of Kukje Pharma Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Everest Industries Limited
NSE:EVERESTIND
|
$65.00 Million |
|
Redtone International Bhd
KLSE:0032
|
$65.01 Million |
|
VELA TECHNOL.PLC LS-0001
F:IBNN
|
$65.03 Million |
|
Amoeba SA
PA:ALMIB
|
$65.03 Million |
|
Catalyst Bancorp Inc
NASDAQ:CLST
|
$64.99 Million |
|
Urja Global Limited
NSE:URJA
|
$64.95 Million |
|
Wooree Bio Co.Ltd
KQ:082850
|
$64.91 Million |
|
Linc Limited
NSE:LINC
|
$64.90 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Kukje Pharma Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 84,944,087,230 to 89,541,787,460, a change of 4,597,700,230 (5.4%).
- Net income of 5,205,175,380 contributed positively to equity growth.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩5.21 Billion | +5.81% |
| Other Changes | ₩-607.48 Million | -0.68% |
| Total Change | ₩- | 5.41% |
Book Value vs Market Value Analysis
This analysis compares Kukje Pharma Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.07x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.23x to 1.07x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩3830.48 | ₩4710.00 | x |
| 2018-12-31 | ₩3808.95 | ₩4710.00 | x |
| 2019-12-31 | ₩3313.71 | ₩4710.00 | x |
| 2020-12-31 | ₩3833.28 | ₩4710.00 | x |
| 2021-12-31 | ₩3552.70 | ₩4710.00 | x |
| 2022-12-31 | ₩3656.47 | ₩4710.00 | x |
| 2023-12-31 | ₩4194.43 | ₩4710.00 | x |
| 2024-12-31 | ₩4397.39 | ₩4710.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Kukje Pharma Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.81%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.33%
- • Asset Turnover: 0.95x
- • Equity Multiplier: 1.85x
- Recent ROE (5.81%) is above the historical average (-1.43%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 1.25% | 0.88% | 0.74x | 1.90x | ₩-6.52 Billion |
| 2013 | 2.87% | 1.39% | 1.03x | 2.01x | ₩-4.16 Billion |
| 2014 | -13.65% | -5.66% | 1.04x | 2.31x | ₩-12.01 Billion |
| 2015 | -8.71% | -5.05% | 0.86x | 2.00x | ₩-12.77 Billion |
| 2016 | 1.15% | 0.64% | 0.93x | 1.92x | ₩-5.98 Billion |
| 2017 | 1.61% | 0.89% | 0.94x | 1.94x | ₩-5.68 Billion |
| 2018 | 3.19% | 2.04% | 0.85x | 1.84x | ₩-4.67 Billion |
| 2019 | -7.81% | -4.28% | 0.83x | 2.21x | ₩-10.85 Billion |
| 2020 | 3.13% | 1.69% | 0.90x | 2.07x | ₩-4.85 Billion |
| 2021 | -2.27% | -1.30% | 0.86x | 2.04x | ₩-8.42 Billion |
| 2022 | 4.80% | 2.81% | 0.93x | 1.84x | ₩-3.85 Billion |
| 2023 | -9.91% | -6.22% | 0.83x | 1.92x | ₩-16.91 Billion |
| 2024 | 5.81% | 3.33% | 0.95x | 1.85x | ₩-3.75 Billion |
Industry Comparison
This section compares Kukje Pharma Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $401,390,357,055
- Average return on equity (ROE) among peers: 0.79%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Kukje Pharma Co Ltd (002720) | ₩95.32 Billion | 1.25% | 0.89x | $65.00 Million |
| Dongwha Pharm.Co.Ltd (000020) | $252.93 Billion | 10.38% | 0.28x | $113.83 Million |
| Yuhan Corp. (000100) | $407.93 Billion | 10.79% | 0.55x | $4.57 Billion |
| Yuhan Corp Preferred (000105) | $1.65 Trillion | 2.42% | 0.28x | $59.61 Million |
| Yuyu Pharma (000220) | $69.50 Billion | 3.97% | 0.28x | $46.55 Million |
| Yuyu Pharma Inc (000225) | $117.04 Billion | 1.10% | 0.32x | $17.67 Million |
| Yuyu Pharma Inc (000227) | $78.29 Billion | 7.52% | 0.42x | $42.93 Million |
| Ildong Holdings Co Ltd (000230) | $169.10 Billion | -60.53% | 4.10x | $76.14 Million |
| Samil Pharm (000520) | $127.83 Billion | 1.30% | 1.90x | $127.90 Million |
| Donga Socio Holdings (000640) | $875.86 Billion | 17.02% | 0.60x | $427.15 Million |
| Jw Pharmac (001060) | $265.44 Billion | 13.94% | 1.43x | $476.78 Million |
About Kukje Pharma Co Ltd
Kukje Pharma Co., Ltd. engages in manufacturing, importing, exporting, selling, and distributing pharmaceutical products. The company offers pharmaceutical products, including ETC and OTC products, raw materials, intermediates, and side chain products, as well as cosmetics and health care products. Its products include cephalosporins, quinolones, tetracycline, aminoglycosides, macrolides, other a… Read more